Also provided are methods of Manufacturing Processes and the use of Crystal forms.Claim 1: 4 - (2 - methyl - pyrimidin-2-yl) - 7 - (4 - (trifluoromethoxy) phenyl) - 3,4 - dihidrobenzo [f] [1,4] oxazepin - 3 (2H) - One (L form Crystalline Compound (i), characterized by an x-ray Powder diffractogram Peaks that includes the following: 23.8 12.3, and 27.2 u00ba2q + 0.2 u00ba2q as. Mine in a diffractometer using cu Ka Radiation at a Wavelength of 15406 angstroms.Claim 3: 4 - (2 - methyl - pyrimidin-2-yl) - 7 - (4 - (trifluoromethoxy) phenyl) - 3,4 - dihidrobenzo [f] [1,4] oxazepin - 3 (2H) - One (Crystalline Form I of the compound (ii), characterized by an x-ray Powder diffractogram Peaks that includes the following u00ba2q: 15.7, 17.5 and 20.3 + / - 0.2 u00ba2q as dete In a rmina diffractometer using cu Ka Radiation at a Wavelength of 15406 angstroms.Claim 5: 4 - (2 - methyl - pyrimidin-2-yl) - 7 - (4 - (trifluoromethoxy) phenyl) - 3,4 - dihidrobenzo [f] [1,4] oxazepin - 3 (2H) - One (Crystalline Form I of compound (iii), characterized by an x-ray Powder diffractogram Peaks that includes the following: 24.1 13.6, 20.6 and u00ba2q + 0.2 u00ba2q as det Ends in a diffractometer using cu Ka Radiation at a Wavelength of 15406 angstroms.Claim 7: 4 - (pyrimidin-2-yl methanesulphonic acid Sulphuric Acid - 2 - methyl) - 7 - (4 - (trifluoromethoxy) phenyl) - 3,4 - dihidrobenzo [f] [1,4] oxazepin - 3 (2H) - One (Crystalline Form I of the compound (iv) characterized by x-ray Powder diffractogram comprising following Peaks: 18.9 20.6 16.5, and u00ba2q [0 u00ba2q, 2, as determined in a diffractometer using cu Ka Radiation at a Wavelength of 15406 angstroms.Claim: 9 bencensulf u00f3nico acid 4 - (2 - methyl - pyrimidin-2-yl) - 7 - (4 - (trifluoromethoxy) phenyl) - 3,4 - dihidrobenzo [f] [1,4] oxazepin - 3 (2H) - One (Crystalline Form I of the compound (V) characterized by x-ray Powder diffractogram comprising following Peaks: 8.0 8.6 and u00ba2q 13.9 + / - 0.2 u00ba2q, as
